



NEWS RELEASE

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

2025-12-17

LANGHORNE, Pa.--(BUSINESS WIRE)-- **Savara Inc.** (Nasdaq: **SVRA**) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will present and host one on one meetings at the 44th Annual J.P. Morgan Healthcare Conference.

Date/Time of Presentation: Wednesday, January 14, 5:15pm PT/8:15pm ET

Presenter: Matt Pauls, Chair and Chief Executive Officer, Savara

Location: Westin St. Francis, San Francisco, Elizabethan B Room

The live webcast and subsequent replay will be available on the **"Events & Presentations"** section of the Company's corporate website and will be archived for 30 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary investigational eFlow[®] Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com and [LinkedIn](#).

*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not

approved in any indication. MOLBREEVI is a trademark of Savara Inc.

Media and Investor Relations Contact

Savara Inc.

Temre Johnson, Executive Director, Corporate Affairs

ir@savarapharma.com

Source: Savara Inc.